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S354 Poster Session IIhave amatched related donor.While transplant outcomes withHLA
matched unrelated donors continue to improve, this requires strin-
gent HLA matching which puts ethnic minorities at a disadvantage.
In this scenario, umbilical cord blood (UCB) has proven to be a valu-
able alternative source of hematopoietic stem cells as it allows for
successful engraftment and decreased GVHD for a greater degree
of HLA disparity. This is of particular importance for the Hispanic
and African American populations in theUnited States who often re-
ceive ethnically mismatched products due to low representation in
the donor pool despite increased recruitment efforts.
The St. Louis Cord Blood Bank (SLCBB) retrospectively evalu-
ated outcomes for 727 patients based on recipient/donor ethnic
match. 543 (74.7%) patients were matched and 184 (25.3%) were
not ethnically matched. Ninety two percent of all patients received
singleton cord blood transplant and 8 percent received dual cord
blood transplant with both products shipped from the SLCBB. Pa-
tient and product characteristics are presented in Table 1.
There were no differences between the groups with respect to ex-
posure to TBI, TNC dose/kg, CD34 dose/kg, and CFU dose/kg.
There was also no correlation between groups with respect to inci-
dence and severity of acute and chronic graft versus host disease
(p..05). Although the ethnically matched group had a higher degree
of HLAmatch (p\.05) time to neutrophil recovery was not impacted
(p..05; median days matched5 22, median days unmatched5 20).
Survival did not differ between the groups at 100 day and $ 1 year
time points (p..05).
This analysis supports the continued use of UCB as a source of he-
matopoietic reconstitution for all populations.
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IV BUSULFAN BASED CONDITIONING REGIMEN FOR HAPLOIDENTICAL
TRANSPLANTATION
Gayoso, J., Balsalobre, P., Serrano, D., Kwon,M., Bu~no, I., Rodriguez, G.,
Anguita, J., Perez Corral, A., Dıez-Martın, J.L. HGU Gregorio
Mara~non, Madrid, Spain
Introduction: Haploidentical transplant (HAPLO) offers the op-
portunity for a cure to those patients without any other available do-
nor. Following Luznik L et al experience (BBMT 2008; 14:641-650)
with a non-myeloablative schemawhere relapses were themain issue,
we developed our own conditioning model using IV busulfan (3,2
mg/kg on day -3) instead of 200cGy TBI, while maintaining post-
transplant high dose cyclophosphamide for GVHD prophylaxis on
days +3 and +4 followed by cyclosporine and MMF. Due to encour-
aging results with our initial experience, IV busulfan was increased to
3,2 mg/kg/day for 2 days in order to reduce relapse incidence and not
to increase transplant related morbidity and mortality (TRM).
Patients and Methods: From Dec-2007, 12 patients (9 males, me-
dian age 39y range 19-55) have received an HAPLO at our institu-
tion for the treatment of AML (3), ALL (1), MDS (1) Myeloma (2)
or Hodgkin’s disease (5), all of them in advanced phases of their dis-
eases. The conditioning regimen consisted of Fludarabine 30mg/m2
for 5 days, Cyclophosphamide 14,5mg/kg for 2 days and IVBusulfan
3,2 mg/kg for 1 day was used in 7 patients and 3,2 mg/kg for 2 days in
the last 5. Bone marrow was the source of progenitors in 10 and
GCSF mobilized peripheral blood without T-depletion in 2. Eight
had received a previous autologous (6) or umbilical cord blood trans-
plant (2, 1 after graft failure).
Results: Median follow up is 12.5 months (0.5-31mo). All patients
engrafted properly. Toxicities of the conditioning regimen included
grade1-2 mucositis (9) and infections (febrile neutropenia and CMV
reactivations in 11, and 1 Pseudomona vulvar cellulitis). Only 1 pa-
tient died from toxicity before day +100 (VOD/MOFat +15d, refrac-
tory ALL). AcuteGVHDgrade II-IV affected to 4/11 patients, being
grade III-IV in 2. Only 2 out of 8 cases at risk developed chronic
GVHD that was extensive in 1. After a median time of 6.5 mo
(2.5-30 mo), 7 patients are in continuous remission and 2 patients
are alive in relapse. Two patients died beyond 1 year: 1 progressive
multifocal leukoencephalopaty at +14 mo and relapse and progres-
sion of AML at +19 mo, respectively.
Conclusions: In our limited experience, IV Busulfan was well toler-
ated as part of the conditioning regimen for HAPLO. A potential re-
duction in relapse incidence without an increase in TRM would be
obtained by this approach. HAPLO is a good chance for rescueing
patients in graft failure after cord blood transplant.406
REAL-TIME QUANTITATIVE-PCR (qrt-PCR) USING AlleleSEQR TECHNOL-
OGY: TO ASSESS CHIMERISM IN PEDIATRICS PATIENTS UNDERGOING
HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
Khan, S.1, Olszewski, M.1, Huang, W.1, Kletzel, M.1,2 1Children’s Me-
morial Hospital, Chicago, IL; 2Northwestern University Feinberg School
of Medicine, Chicago, IL
Post-transplantation chimerismmonitoring in HSCT is pivotal to
assess engraftment, rejection or relapse. There has been previous
studies performed using qrt-PCR to detect chimerism by different
technologies. Our purpose is to describe qrt-PCR as a sensitive
and reproducible method to assess chimerism using AlleleSEQR
(Cellera). A total of 112 peripheral blood samples were obtained
from 43 allogeneic HSCT. qrt-PCR (Applied Biosystems 7500)
was performed using 34 alleles that are designed to be a bi-allelic in-
sertion/deletion (indel) polymorphism in the human genome. Ex-
traction of DNA was performed using QIAamp DNA Blood Mini
Kit (Qiagen) of both donor and recipient cells pre transplant (n 5
43) then were screened for their informative alleles. At least 2 alleles
were chosen that amplified with a CT value less than 34.0, but greater
than or equal to 30.0 with aDCT of -2.0 to +2.0. Post transplant sam-
ples (n5 69) were then separated in three subsets: TotalWBC using
the Erythrocyte Lysis Buffer (Qiagen), T-cell and Myeloid cells us-
ing RosetteSep T-cell and Myeloid Enrichment kits (Stem Cell
Technologies) followed by DNA extraction and quantitation using
the chosen informative alleles. To determine the sensitivity a serial
dilution curve is shown in Table 1 with a r 5 1. Reproducibility
was validated by a reference lab using 18 unknown samples with
a correlation of r 5 0.98. Subset analysis was reported as percent
donor total: 91.9 6 2.22, median 99.6 (35.5-100), T-cell: 93.7 6
2.56, median 99.6 (29.6-100), myeloid: 91.2 6 3.23, median 99.9
(9.30-100) with a p value of\ 0.0001. Results indicate that the use
of this technology is reproducible, sensitive and accurate to assess
donor Chimerism in pediatric patients undergoing HSCT.
Table 1. qrt-PCR Sensitivity Determination
Serial Dilution qrt-PCR Results0.1% 0.086%
0.2% 0.16%
1% 1.0%
2% 1.9%
10% 9.2%407
RAPID IDENTIFICATION OF INFORMATIVE MARKERS FROM MULTIPLE
DONORS FOR STEM CELL TRANSPLANT ENGRAFTMENT MONITORING
Sigua, C.L., Santini, C.D., Bost, D.A. Celera Corporation, Alaemda, CA
Wehave designed a system of RUOqPCR assays and software en-
abling highly sensitive, stem cell engraftment monitoring. Our ap-
proach allows for facile quantification of minute amounts of minor
components in a mixture, while also reducing workflow and analysis
burdens. This approach expands the linear dynamic range over
which increasing mixed chimerism may be monitored, effectively in-
creasing the probability of detecting adverse transplant events ear-
lier.
We utilize a panel of 34 qPCR research assays to bi-allelic indels
across the genome. Our system affords rapid pre-transplant marker
identification and quantification of recipient levels post-transplant.
It enables marker identification and quantification to occur within
a few hours and without the need for capillary electrophoresis. In
an effort to decrease our current sample volume requirements, in-
crease throughput and enable multiple donor screening scenarios,
we evaluated a multiplexed assay approach for marker identification.
The qPCR assays are multiplexed, with 2-3 assays per well. The
probes are labeled with FAM-BHQ1, California Orange-BHQ1
and Quasar 670-BHQ2. The presence of alleles is scored in relation
to amplification of an endogenous control assay. The results of sam-
ples within a group are compared against each other to identify infor-
mative markers for each sample. Up to eight samples can be
Poster Session II S355evaluated in a single 96-well plate, with a variable number and con-
figuration of samples within a group.
Results: The described multiplexed qPCR approach yielded results
which were comparable to those generated when using the assays in-
dividually. When the single assay algorithms were applied to the
samples tested in the multiplexed format, the same genotyping calls
were made and informative alleles identified.
Conclusions: Use of this RUO, multiplexed qPCR system for
screening of multiple specimens enabled rapid identification of in-
formative markers for all samples without post-PCR processing,
while dramatically decreasing sample volume requirements.408
DONOR AND RECIPIENT HBV IMMUNITY BEFORE TRANSPLANTATION SI-
MULTANEOUSLY AFFECTS THE ACQUISITION OF HBV IMMUNITY AFTER
UNRELATED-DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION
Luo, Y., Hu, Y., Shi, J., Tan, Y., Lai, X., He, J., Zheng, W., Cai, Z.,
Huang, H. The First Affliated Hospital, School of Medicine Zhejiang Uni-
versity, Hangzhou, Zhejiang, China
Introduction: Patients undergone allogeneic hematopoietic stem
cell transplantation (HSCT) are accompanied by intensive chemo-
therapy and immunosuppression. Such patients are in high risk of
hepatitis B virus (HBV) infection. Recovery of recipient immunity
on HBV post-transplantation has a potential role in HBV preven-
tion. In the current study, we performed a retrospective analysis of
recipient immunity on HBV after HSCT and attempted to find
out some factors associated with the HBV immunity acquisition
posttransplantation.
Patients and Methods: Between June 1999 and March 2009, 135
HBsAg(-) patients undergone unrelated HSCT were enrolled.
HBV serum markers including HBsAg, HBeAg, HBeAb, HBsAb
andHBcAbwere tested for donor screen and recipients. HBV immu-
nity was defined as positive HBsAb within 6 months posttransplan-
tation. Patients were divided into 4 groups (R+/D+, R+/D-, R-/D+
and R-/D-; R represents recipient and D represents donor) accord-
ing to + or -HBsAb in recipients and donors. The data were analyzed
using spss v17.0 software.
Results: Pretransplantation characteristics of patients and donors
were summarized in Table 1. Multivariate analysis showed that
primary disease type, donor and recipient’s sex and age, HLA dis-
parity and conditioning regimen containing ATG were not statisti-
cally different among the 4 groups. In total 42 of 42 (100%), 22 of 32
(68.8%), 24 of 26 (92.3%) and 0 of 35 (0%) patients acquired HBV
immunity posttransplantation in D+/R+, D+/R-, D-/R+ and D-/R-
group respectively (p\0.05 between D+/R+ and D+/R- group, D+/
R+ and D-/R- group, D+/R- and D-/R+ group, D+/R- and D-/R-
group, D-/R+ and D-/R- group) indicating HBsAb in both donors
and recipients had a significant favorable effect on maintaining the
HBV immunity of recipients with HBsAb before transplantation. A
total of 2 recipients experienced HBV reactivation post-
transplantation(1 in D-/R+ and D-/R- group each) indicating HBV
immunity in donors have protective effects on HBV reactivation.
The mean duration from stem cell transfusion to HBsAb appearance
was 25, 28, 20 and 24 days in the correspoinding group respectively
(p.0.05).
Conclusion:Our data support that donor and recipientHBV immu-
nity before transplantation can simultaneously affect the acquisition
of HBV immunity and have a vital role in HBV reactivation after un-
related-donor HSCT. HBV vaccination should be performed inTable 1. Pretransplantation Characteristics of Patients and donors
D+/R+ group D+/2 g
Median recipient age(years) 25 27
Male recipient number 27 20
Conditioning regimen containing ATG 5 3
Donor mean age 30 28
HLA mismatched 5 3
Positive HBcAb in recipients 12 8
Total number 42 32both donors and recipients who have no HBV immunity before
transplantation.409
STREAMLINED ANALYSIS, QUANTIFICATION AND LONG TERMMONITOR-
ING OF POST-BONE MARROW TRANSPLANT CHIMERISM STR DATA
Kristt, D.2, Snyder-Leiby, T.1, Hulce, D.1, Liu, J.1, Nguyen, P.1 1SoftGe-
netics, State College, PA; 2Hadassah Medical Center, Jerusalem, Israel
Over the last decade, hematopoietic stem cell transplantation
(HSCT) has become the main treatment for blood related and au-
toimmune diseases. After HSCT, chimerism monitoring plays
a critical role in predicting the effects of engraftment, GVHD
and disease relapse. We are introducing ChimerMarker software
which integrates raw data analysis to allele identification, chime-
rism quantification, reporting, and longitudinal monitoring. This
program eliminates the need for manual data transfer from geno-
typing software to chimerism analysis software and will automati-
cally identify informative loci using a patient specific
chimertyping panel. After identification, percent chimerism and
statistics for reliability assessment of each informative locus are cal-
culated. Average chimerism is calculated for all informative loci
that pass reliability assessment. Coefficient of variation, standard
deviation, margin of error and number of informative loci are re-
ported. Results can be printed. All samples and chimertyping panel
can be saved within one project file. Subsequent samples for a par-
ticular patient can be easily appended to the project file and quan-
tified within seconds. By having all test samples for one patient in
one file, the software can construct a longitudinal graph for long
term monitoring of chimeric status. This graph may be used to an-
ticipate changes in the chimerism state that may warrant drug in-
tervention to prevent GVHD or disease relapse. ChimerMarker
software is superior to the current method of using spreadsheets.
It eliminates error prone data transfer, time consuming manual
loci identification, repetitive calculations, and allows for electronic
record keeping of all samples, calculations, and longitudinal graph
in one project file. This study uses data collected from a five-year
post-bone marrow transplant patient. DNA was amplified using
Profiler Plus. Analysis, including: allele calls, determining infor-
mative loci, calculating percent chimerism and quality control met-
rics, and monitoring report graphing, was completed in
ChimerMarker in approximately 30 minutes.410
UTILIZATION OF NURSE PRACTITIONERS IN BONE MARROW HARVESTS
Turner, K.J., Tarin II, R. Cincinnati Children’s Hospital Medical Center,
Cincinnati, OH
Over 100 bone marrow transplants are performed at Cincinnati
Children’s Hospital Medical center each year. Those recipients for-
tunate enough to have a matched related donor number from ten to
twelve yearly. These donors are harvested at our facility through the
efforts of our harvest team comprised of two physicians and a nurse
practitioner. Bone marrow harvests require meticulous attention to
detail during the collection and post when the marrow is filtered
and transported to a processing center in preparation for infusion
into the recipient. Specifics about how the nurse practitioner func-
tions as a key member of the harvest team are outlined.before Transplantation
roup D2/R+ group D2/R2 group p value
28 27 >0.05
16 21 >0.05
4 3 >0.05
29 31 >0.05
4 3 >0.05
7 9 >0.05
26 35
